TScan Therapeutics To Host Virtual KOL Event To Discuss Results From Ongoing Phase 1 Trial Of TSC-100 And TSC-101 Presented At The 65th ASH Annual Meeting And Exposition

Author: Benzinga Newsdesk | December 04, 2023 05:22pm

TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the Company will host a virtual key opinion leader (KOL) event on Monday, December 11, at 8:00 a.m. ET to discuss highlights from its poster presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition. Following the prepared remarks, the call will be opened for a live question and answer session. To submit a question, please reach out to questions@lifesciadvisors.com.

 

The event will provide an in-depth review of the presentation related to lead TCR-T cell therapy candidates, TSC-100 and TSC-101, designed to target HA-1 and HA-2, respectively, to treat residual disease and prevent relapse in patients with acute myeloid leukemia, acute lymphocytic leukemia or myelodysplastic syndromes undergoing allogeneic haploidentical hematopoietic cell transplantation with reduced intensity conditioning. (NCT05473910)

Featured speakers include:

• Monzr M. Al Malki, M.D., Associate Professor in the Department of Hematology & Hematopoietic Cell Transplantation and Director of the Unrelated Donor Bone Marrow Transplant and Haploidentical Transplant Programs at City of Hope
• Gavin MacBeath, Ph.D., Chief Executive Officer, TScan Therapeutics
• Debora Barton, M.D., Chief Medical Officer, TScan Therapeutics
• Shrikanta Chattopadhyay, M.D., M.M.Sc., Senior Vice President of Medical and Translational Medicine, TScan Therapeutics
  
   

Registration for the live event can be found here. A replay will be available on the "Events and Presentations" section of the Company's website at ir.tscan.com.

Posted In: TCRX